Pharma Times
JULY 23, 2025
Dr Catherine Caulfield, CEO of Ovagen said: “What we have developed isn’t incremental, it’s a complete rethink of the vaccine manufacturing process. Our germ free egg platform eliminates bacterial contamination and reduces the need for antibiotics in vaccine production, while delivering significantly higher viral yield.
Pharmaceutical Technology
JUNE 13, 2025
June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GSK’s vaccine leverages GMMA technology. GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. Can pharma tariffs “Make America Manufacture Again”?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 5, 2025
Using real-world data to support vaccine outreach and education Buy Reports Newsletters PT News GSK’s world-first gonorrhoea vaccine launched in England The immunisation programme aims to reduce rising gonorrhoea rates and address antibiotic-resistant strains. GSK’s 4CMenB is not a newly approved vaccine.
Pharma Times
JULY 10, 2025
The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. Series A to advance radioligand therapy platform Jul 9, 2025 VarmX secures US approval to begin phase 3 trial of urgent surgery treatment Jul 8, 2025 News alerts This field is required.
Pharmaceutical Technology
JUNE 20, 2025
The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. Can pharma tariffs “Make America Manufacture Again”? Credit: Department of Health Abu Dhabi.
Pharma Times
JULY 28, 2025
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Moderna’s updated COVID-19 vaccine receives positive EMA opinion by John Pinching | 28th Jul 2025 | News CHMP recommends authorization for LP.8.1-targeting
Pharma Times
JULY 1, 2025
The vaccine showed a 26.6% higher relative vaccine efficacy compared with the existing option. Across all age groups, risk profiles and vaccination histories, the results were consistently strong. The severity of this past flu season underscores the need for more effective vaccines.”
Expert insights. Personalized for you.
Let's personalize your content